Walled Lake Planning & Wealth Management LLC Sells 1,315 Shares of Merck & Co., Inc. (NYSE:MRK)

Walled Lake Planning & Wealth Management LLC lessened its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 2.3% during the fourth quarter, Holdings Channel reports. The fund owned 56,879 shares of the company’s stock after selling 1,315 shares during the period. Merck & Co., Inc. comprises 2.5% of Walled Lake Planning & Wealth Management LLC’s holdings, making the stock its 16th biggest holding. Walled Lake Planning & Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $4,359,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP increased its stake in Merck & Co., Inc. by 2.4% in the third quarter. Wellington Management Group LLP now owns 49,559,078 shares of the company’s stock valued at $3,722,381,000 after acquiring an additional 1,152,241 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Merck & Co., Inc. by 1.2% during the third quarter. Franklin Resources Inc. now owns 39,262,359 shares of the company’s stock valued at $2,948,995,000 after buying an additional 457,650 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Merck & Co., Inc. by 13.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 28,981,674 shares of the company’s stock valued at $2,221,156,000 after buying an additional 3,484,786 shares during the last quarter. Morgan Stanley grew its stake in shares of Merck & Co., Inc. by 17.1% during the second quarter. Morgan Stanley now owns 26,289,496 shares of the company’s stock valued at $2,044,534,000 after buying an additional 3,832,086 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Merck & Co., Inc. by 41.3% during the third quarter. Invesco Ltd. now owns 19,461,290 shares of the company’s stock valued at $1,461,738,000 after buying an additional 5,687,973 shares during the last quarter. 72.88% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently issued reports on MRK. Barclays raised their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, April 12th. StockNews.com began coverage on Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Morgan Stanley reduced their price objective on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 6th. Mizuho initiated coverage on shares of Merck & Co., Inc. in a report on Friday, April 1st. They set a “buy” rating and a $100.00 target price for the company. Finally, JPMorgan Chase & Co. dropped their target price on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, January 28th. Eight investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Buy” and a consensus target price of $90.69.

MRK traded down $0.42 on Friday, hitting $90.41. The company had a trading volume of 10,308,067 shares, compared to its average volume of 11,242,952. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.27 and a quick ratio of 1.02. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $91.40. The stock has a fifty day simple moving average of $83.97 and a 200-day simple moving average of $80.70. The firm has a market capitalization of $228.63 billion, a P/E ratio of 16.17, a P/E/G ratio of 1.20 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings data on Thursday, April 28th. The company reported $2.14 EPS for the quarter, topping the consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 49.57%. The business had revenue of $15.90 billion during the quarter, compared to analyst estimates of $14.64 billion. During the same period last year, the business posted $1.40 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 31.6% compared to the same quarter last year. Equities research analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.